Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 601–700 of 1,015
Rational construction of a reversible arylazo-based NIR probe for cycling hypoxia imaging in vivo
Zhang, Y., Zhao, W., Chen, Y., Yuan, H., Fang, H., Yao, S., Zhang, C., Xu, H., Li, N., Liu, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22855-0 · Cited by 90
Selective Thrombosis of Tumor for Enhanced Hypoxia‐Activated Prodrug Therapy
Ma, Z., Zhang, Y., Dai, X., Zhang, W., Foda, M. F., Zhang, J. C., Zhao, Y., & Han, H. (2021) · Advanced Materials · doi:10.1002/adma.202104504 · Cited by 89
Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P. D. A., Delgoffe, G. M., & Curran, M. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
Sun, J., Wang, J., Hu, W., Wang, Y., Zhang, Q., Hu, X., Chou, T., Zhang, B., Gallaro, C., Halloran, M., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c02528 · Cited by 92
Deng, H., Chen, Y., Li, P., Hang, Q., Zhang, P., Jin, Y., & Chen, M. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.09.001 · Cited by 99
Kim, H.-S., Wannatung, T., Lee, S., Yang, W. K., Chung, S. H., Lim, J., Choe, W., Kang, I., Kim, S. S., & Ha, J. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0719-0 · Cited by 90
Gene expression and hypoxia in breast cancer
Favaro, E., Lord, S., Harris, A. L., & Buffa, F. M. (2011) · Genome Medicine · doi:10.1186/gm271 · Cited by 88
Noncanonical Amino Acids to Improve the pH Response of pHLIP Insertion at Tumor Acidity
Onyango, J. O., Chung, M. S., Eng, C., Klees, L. M., Langenbacher, R. E., Yao, L., & An, M. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201409770 · Cited by 86
Guan, Q., Li, Y., Li, W., & Dong, Y. (2018) · Chemistry - An Asian Journal · doi:10.1002/asia.201801221 · Cited by 92
Salem, A., Little, R. A., Latif, A., Featherstone, A. K., Babur, M., Peset, I., Cheung, S., Watson, Y., Tessyman, V., Mistry, H. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3932 · Cited by 92
Bacteria‐Assisted Selective Photothermal Therapy for Precise Tumor Inhibition
Wang, S., Liu, X., Li, B., Fan, J., Ye, J., Cheng, H. L., & Zhang, X. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201904093 · Cited by 90
Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis
Lin, C.-W., Wang, L.-K., Wang, S.-P., Chang, Y.-L., Wu, Y.-Y., Chen, H.-Y., Hsiao, T.-H., Lai, W.-Y., Lu, H.-H., Chang, Y.-H., et al. (2016) · Nature Communications · doi:10.1038/ncomms13867 · Cited by 86
“Daxx (death domain-associated protein) has been shown to directly interact with and suppress multiple transcription factors, including Etwenty six 1, glucocorticoid receptor, androgen receptor (AR), nuclear factor-k B, p53, E2F1 and Pax gene family members, and it is involved in multiple biological…”
Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay
Marampon, F., Gravina, G. L., ZANI, B. M., Popov, V. M., Fratticci, A., Cerasani, M., Genova, D. D., Mancini, M., Ciccarelli, C., Ficorella, C., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2358 · Cited by 86
Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
Li, X., Liu, Y., & Tian, H. (2018) · Bioinorganic Chemistry and Applications · doi:10.1155/2018/8276139 · Cited by 90
Beyond energy storage: roles of glycogen metabolism in health and disease
Zhang, H., Ma, J., Tang, K., & Huang, B. (2020) · FEBS Journal · doi:10.1111/febs.15648 · Cited by 89
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Progress and perspective on hydrogen sulfide donors and their biomedical applications
Song, Z., Zhao, L., Ma, T., Osama, A., Shen, T., He, Y., & Fang, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21913 · Cited by 92
Dong, Z., Wang, C., Gong, Y., Zhang, Y., Fan, Q., Hao, Y., Li, Q., Wu, Y., Zhong, X., Yang, K., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c02688 · Cited by 88
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 100
Understanding and targeting resistance to anti-angiogenic therapies.
Clarke, J. M., & Hurwitz, H. I. (2013) · PubMed · doi:10.3978/j.issn.2078-6891.2013.036 · Cited by 82
Zhang, L., Sun, Z., Bian, Y., & Kulkarni, A. B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.003 · Cited by 87
Bollineni, V. R., Kerner, G. S. M. A., Pruim, J., Steenbakkers, R. J. H. M., Wiegman, E. M., Koole, M. J. B., de Groot, E. H., Willemsen, A. T. M., Luurtsema, G., Widder, J., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.115014 · Cited by 89
Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics
Gao, F., Wu, J., Gao, H., Hu, X., Liu, L., Midgley, A. C., Liu, Q., Sun, Z., Liu, Y., Ding, D., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119635 · Cited by 85
Tumor necrosis: A synergistic consequence of metabolic stress and inflammation
Yee, P. P., & Li, W. (2021) · BioEssays · doi:10.1002/bies.202100029 · Cited by 85
A Mitochondria‐Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects Under Hypoxia
Lv, W. Y., Zhang, Z., Zhang, K. Y., Yang, H., Liu, S., Xu, A., Guo, S., Zhao, Q., & Huang, W. (2016) · Angewandte Chemie · doi:10.1002/ange.201604130 · Cited by 85
Real-Time Bioluminescence Imaging of Nitroreductase in Mouse Model
Feng, P., Zhang, H., Deng, Q., Liu, W., Yang, L., Li, G., Chen, G., Du, L., Ke, B., & Li, M. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01160 · Cited by 86
Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3890 · Cited by 76
Monocarboxylate Transporters 1–4 in NSCLC: MCT1 Is an Independent Prognostic Marker for Survival
Eilertsen, M., Andersen, S., Al‐Saad, S., Kiselev, Y., Dønnem, T., Stenvold, H., Pettersen, I., Al-Shibli, K. I., Richardsen, E. H., Busund, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105038 · Cited by 87
Janji, B., Berchem, G., & Chouaïb, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00887 · Cited by 88
Tseng, S. ‐., Kempson, I. M., Huang, K., Li, H., Fa, Y., Ho, Y., Liao, Z., & Yang, P. (2018) · ACS Nano · doi:10.1021/acsnano.8b02813 · Cited by 88
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Abou Khouzam, R., Goutham, H. V., Zaarour, R. F., Chamseddine, A. N., Francis, A., Buart, S., Terry, S., & Chouaib, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.003 · Cited by 83
Zhang, M., Guo, X., Wang, M., & Liu, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.026 · Cited by 84
Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment
Maslah, H., Skarbek, C., Pèthe, S., & Labruère, R. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112670 · Cited by 87
Recent Progress in the Development of Multifunctional Nanoplatform for Precise Tumor Phototherapy
Liu, J., Shi, J., Nie, W., Wang, S., Liu, G., & Cai, K. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001207 · Cited by 87
Medicinal Chemistry of Drugs with N-Oxide Functionalities
Kobus, M., Friedrich, T., Zorn, E., Burmeister, N., & Maison, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00254 · Cited by 92
Hypoxia and Predicting Radiation Response
Hill, R. P., Bristow, R. G., Fyles, A., Koritzinsky, M., Milosevic, M., & Wouters, B. G. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.05.004 · Cited by 99
Ubiquitin-specific Protease 19 (USP19) Regulates Hypoxia-inducible Factor 1α (HIF-1α) during Hypoxia
Altun, M., Zhao, B., Velasco, K., Liu, H., Hassink, G. C., Paschke, J., Pereira, T., & Lindsten, K. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.305615 · Cited by 92
Research progress on tumor hypoxia-associative nanomedicine
Xu, X., Chen, S., Yi, N.-B., Li, X., Chen, S., Lei, Z., Cheng, D., & Sun, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.003 · Cited by 87
Zhao, X., Du, J., Sun, W. C., Fan, J., & Peng, X. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.4c00399 · Cited by 88
Dual-Specificity Phosphatases as Molecular Targets for Inhibition in Human Disease
Ríos, P., Nunes‐Xavier, C. E., Tabernero, L., Köhn, M., & Pulido, R. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5709 · Cited by 97
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
Hibernation for space travel: Impact on radioprotection
Cerri, M., Tinganelli, W., Negrini, M., Helm, A., Scifoni, E., Tommasino, F., Sioli, M., Zoccoli, A., & Durante, M. (2016) · Life Sciences in Space Research · doi:10.1016/j.lssr.2016.09.001 · Cited by 82
Lee, C., Lim, K., Kim, S. S., Thien, L. X., Lee, E. S., Oh, K. T., Choi, H.-G., & Youn, Y. S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.011 · Cited by 82
LINE-1 and EPAS1 DNA methylation associations with high-altitude exposure
Childebayeva, A., Jones, T. R., Goodrich, J. M., Lèon‐Velarde, F., Rivera, M. C., Kiyamu, M., Brutsaert, T. D., Dolinoy, D. C., & Bigham, A. W. (2018) · Epigenetics · doi:10.1080/15592294.2018.1561117 · Cited by 105
Hypoxia-active nanoparticles used in tumor theranostic
Wang, Y., Shang, W., Niu, M., Tian, J., & Xu, K. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s196959 · Cited by 82
Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors
Soltani, M., Souri, M., & Moradi Kashkooli, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-98638-w · Cited by 82
Wang, K., Jiang, M., Zhou, J., Liu, Y., Zong, Q., & Yuan, Y. (2022) · ACS Nano · doi:10.1021/acsnano.1c08232 · Cited by 84
Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer
Xiao, S., Shi, H., Zhang, Y., Fan, Y., Wang, L., Xiang, L., Liu, Y., Zhao, L., & Fu, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01373-1 · Cited by 87
Cytotoxic Activity of Herbal Medicines as Assessed in Vitro : A Review
Gavanji, S., Bakhtari, A., Famurewa, A. C., & Othman, E. M. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202201098 · Cited by 124
Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., Joshi, N., Sreebhavan, S., Weinreb, I., Goldstein, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1107 · Cited by 82
Self-citationBimetallic lanthanide complexes that display a ratiometric response to oxygen concentrations
Sørensen, T. J., Kenwright, A. M., & Faulkner, S. (2015) · Chemical Science · doi:10.1039/c4sc03827d · Cited by 88
Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs
O'Connor, L. J., Cázares-Körner, C., Saha, J., Evans, C. N. G., Stratford, M. R. L., Hammond, E. M., & Conway, S. J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.034 · Cited by 82
Hypoxia-tropic Protein Nanocages for Modulation of Tumor- and Chemotherapy-Associated Hypoxia
Huang, X., Zhuang, J., Chung, S. W., Huang, B., Halpert, G., Negrón, K., Sun, X., Yang, J., Oh, Y., Hwang, P. M., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b05399 · Cited by 84
Degradable polyprodrugs: design and therapeutic efficiency
Seidi, F., Zhong, Y., Xiao, H., Jin, Y., & Crespy, D. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00099g · Cited by 85
Cationic telluroviologen derivatives as type‐I photosensitizers for tumor photodynamic theranostics
Sun, Q., Su, Q., Gao, Y., Zhou, K., Song, W., Quan, P., Yang, X., Ge, Z., Zhang, Y., & He, G. (2022) · Aggregate · doi:10.1002/agt2.298 · Cited by 83
Carbonic Anhydrase IX (CAIX) as a Mediator of Hypoxia-Induced Stress Response in Cancer Cells
McDonald, P. C., & Dedhar, S. (2013) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-7359-2_13 · Cited by 85
Dhani, N. C., Serra, S., Pintilie, M., Schwock, J., Xu, J., Gallinger, S., Hill, R. P., & Hedley, D. W. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.284 · Cited by 89
Quantitative measurement of redox potential in hypoxic cells using SERS nanosensors
Jiang, J., Auchinvole, C., Fisher, K., & Campbell, C. J. (2014) · Nanoscale · doi:10.1039/c4nr01263a · Cited by 90
The twisted survivin connection to angiogenesis
Sanhueza, C. T., Wehinger, S., Bennett, J., Valenzuela, M., Owen, G. I., & Quest, A. F. G. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0467-1 · Cited by 93
Cancer stem cells with increased metastatic potential as a therapeutic target for esophageal cancer
Wang, D., Plukker, J. T. M., & Coppes, R. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.010 · Cited by 81
Tao, Y., Zhu, L., Zhao, Y., Yi, X., Zhu, L., Ge, F., Mou, X., Chen, L., Sun, L., & Yang, K. (2018) · Nanoscale · doi:10.1039/c7nr08747k · Cited by 85
Targeting Cancer Stem Cell Redox Metabolism to Enhance Therapy Responses
Luo, M., & Wicha, M. S. (2018) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.10.003 · Cited by 81
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Mylonis, I., Kourti, M., Samiotaki, M., Panayotou, G., & Simos, G. (2017) · Journal of Cell Science · doi:10.1242/jcs.195339 · Cited by 80
Yin, W., Ming, Q., Ke, W., Han, Y., Mukerabigwi, J. F., & Ge, Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.014 · Cited by 80
Tumor Microenvironment Sensitive Nanocarriers for Bioimaging and Therapeutics
Park, H., Saravanakumar, G., Kim, J., Lim, J., & Kim, W. J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000834 · Cited by 88
Wang, Y., Zhang, S., Wang, J., Zhou, Q., Mukerabigwi, J. F., Ke, W., Lu, N., & Ge, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.007 · Cited by 84
Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
Cong, T. D., Lau, J. W., Sun, C., Liu, S., Kha, T., Lim, S. T., Oon, Y. Y., Kwan, Y. P., Ma, J., Mu, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq2216 · Cited by 87
Recent methods of droplet microfluidics and their applications in spheroids and organoids
Wang, Y., Liu, M., Zhang, Y., Liu, H., & Han, L. G. (2023) · Lab on a Chip · doi:10.1039/d2lc00493c · Cited by 91
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma
Liao, C., Hu, L., & Zhang, Q. H. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00876-w · Cited by 98
The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression
Young, L. C., & Hendzel, M. J. (2012) · Biochemistry and Cell Biology · doi:10.1139/bcb-2012-0054 · Cited by 81
CYP450 Enzymes Effect Oxygen-Dependent Reduction of Azide-Based Fluorogenic Dyes
O’Connor, L. J., Mistry, I. N., Collins, S. L., Folkes, L. K., Brown, G., Conway, S. J., & Hammond, E. M. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00276 · Cited by 85
Ziani, L., Buart, S., Chouaïb, S., & Thiery, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950953 · Cited by 84
Stimuli‐Responsive Silica Silanol Conjugates: Strategic Nanoarchitectonics in Targeted Drug Delivery
Mohanan, S., Guan, X., Liang, M., Karakoti, A. S., & Vinu, A. (2023) · Small · doi:10.1002/smll.202301113 · Cited by 88
Brahimi-Horn, M. C., Ben-Hail, D., Ilié, M., Gounon, P., Rouleau, M., Hofman, V., Doyen, J., Mari, B. P., Shoshan‐Barmatz, V., Hofman, P. M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3940 · Cited by 94
Ivey, J. W., Bonakdar, M., Kanitkar, A., Davalos, R. V., & Verbridge, S. S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.019 · Cited by 89
Sun, L., Chen, Y., Kuang, S., Li, G., Guan, R., Liu, J., Ji, L., & Chao, H. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600310 · Cited by 83
Ren, Y. X., Hao, P., Dutta, B., Cheow, E. S. H., Sim, K. H., Gan, C. S., Lim, S. K., & Sze, S. K. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018325 · Cited by 79
Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
Wojtkowiak, J. W., Cornnell, H. C., Matsumoto, S., Saito, K., Takakusagi, Y., Dutta, P., Kim, M., Zhang, X., Leos, R. A., Bailey, K. M., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-014-0026-z · Cited by 79
Silva, V. L., & Al-Jamal, W. T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.013 · Cited by 78
Wei, Z., Yin, X., Cai, Y., Xu, W., Song, C., Wang, Y., Zhang, J., Kang, A., Wang, Z., & Han, W. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s156984 · Cited by 78
Yang, H., Schramek, D., Adam, R. C., Keyes, B. E., Wang, P., Zheng, D., & Fuchs, E. (2015) · eLife · doi:10.7554/elife.10870 · Cited by 76
Advanced Delivery Systems Based on Lysine or Lysine Polymers
Manouchehri, S., Zarrintaj, P., Saeb, M. R., & Ramsey, J. D. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00474 · Cited by 85
Sarnella, A., Ferrara, Y., Auletta, L., Albanese, S., Cerchia, L., Alterio, V., Simone, G. D., Supuran, C. T., & Zannetti, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02345-x · Cited by 84
Zhang, Y., Liu, X., Zeng, L., Zhao, X., Chen, Q., Pan, Y., Bai, Y., Shao, C., & Zhang, J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01956-7 · Cited by 82
Lindskrog, S. V., Birkenkamp‐Demtröder, K., Nordentoft, I., Laliotis, G., Lamy, P., Christensen, E., Renner, D., Andreasen, T. G., Lange, N., Sharma, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1860 · Cited by 91
Varveri, A., Papadopoulou, M., Papadovasilakis, Z., Compeer, E. B., Legaki, A., Delis, A. D., Damaskou, V., Boon, L., Papadogiorgaki, S., Samiotaki, M. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49282-1 · Cited by 91
Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells
Cao, J., Wang, Y., Dong, R., Lin, G., Zhang, N., Wang, J., Lin, N., Gu, Y., Ding, L., Ying, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0711 · Cited by 78
A Zebrafish Model to Study and Therapeutically Manipulate Hypoxia Signaling in Tumorigenesis
Santhakumar, K., Judson, E. C., Elks, P. M., McKee, S., Elworthy, S., van Rooijen, E., Walmsley, S. R., Renshaw, S. A., Cross, S. S., & van Eeden, F. J. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3148 · Cited by 80
Zhong, D., Li, W., Hua, S., Qi, Y., Xie, T., Qiao, Y., & Zhou, M. (2021) · Theranostics · doi:10.7150/thno.55441 · Cited by 76
Vasić, K., Knez, Ž., & Leitgeb, M. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15080227 · Cited by 76
Yang, M., Chang, C.-J., & Chen, L.-Y. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.06.014 · Cited by 76
Zhang, J., Jin, H., Wu, Y., Zheng, Z., Guo, S., Wang, Y., Yang, D., Meng, X., Xu, X., & Zhao, Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02035-9 · Cited by 75
Alexa‐Stratulat, T., Pešić, M., Gašparović, A. Č., Trougakos, I. P., & Riganti, C. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100643 · Cited by 80
Multiparameter persistent homology landscapes identify immune cell spatial patterns in tumors
Vipond, O., Bull, J. A., Macklin, P. S., Tillmann, U., Pugh, C. W., Byrne, H. M., & Harrington, H. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102166118 · Cited by 121
Khouzam, R. A., Zaarour, R. F., Brodaczewska, K. K., Azakir, B., Venkatesh, G. H., Thiery, J., Terry, S., & Chouaïb, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828875 · Cited by 83
Turn-on Fluorescent Biosensors for Imaging Hypoxia-like Conditions in Living Cells
Guisán‐Ceinos, S., Rivero, A. R., Romeo‐Gella, F., Simón‐Fuente, S., Gómez-Pastor, S., Calvo, N., Orrego, A. H., Guisan, J. M., Corral, I., Sanz-Rodrı́guez, F., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c01197 · Cited by 77
Ranasinghe, W. K. B., Xiao, L., Kovac, S., Chang, M., Michiels, C., Bolton, D., Shulkes, A., Baldwin, G. S., & Patel, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054251 · Cited by 76
Microfluidic technologies for anticancer drug studies
Valente, K. P., Khetani, S., Kolahchi, A. R., Sanati‐Nezhad, A., Suleman, A., & Akbari, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.010 · Cited by 78
Ron, A., Deán‐Ben, X. L., Gottschalk, S., & Razansky, D. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3769 · Cited by 78
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.